A randomized, double-blind, 4 way cross-over, placebo controlled trial to evaluate the onset of action of bilastine 20 mg vs. placebo, cetirizine 10 mg, and fexofenadine 120 mg in the Vienna challenge chamber

Trial Profile

A randomized, double-blind, 4 way cross-over, placebo controlled trial to evaluate the onset of action of bilastine 20 mg vs. placebo, cetirizine 10 mg, and fexofenadine 120 mg in the Vienna challenge chamber

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2012

At a glance

  • Drugs Bilastine; Cetirizine; Fexofenadine
  • Indications Allergic rhinitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Mar 2009 Actual patient number (75) added as reported by ClinicalTrials.gov.
    • 08 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top